This podcast discusses the important risks and potential benefits of PD-1 immune checkpoint blockade in patients with thymic epithelial neoplasms. Read the related article "<a href= "http://ascopubs.org/doi/abs/10.1200/JCO.2017.77.3184">Pembrolizumab for Patients With Refractory or Relapsed Thymic Epithelial Tumor: An Open-Label Phase II Trial</a>" on JCO.org

This podcast discusses the important risks and potential benefits of PD-1 immune checkpoint blockade in patients with thymic epithelial neoplasms. Read the related article "Pembrolizumab for Patients With Refractory or Relapsed Thymic Epithelial Tumor: An Open-Label Phase II Trial" on JCO.org

This podcast discusses the important risks and potential benefits of PD-1 immune checkpoint blockade in patients with thymic epithelial neoplasms. Read the related article "<a href="http://ascopubs.org/doi/abs/10.1200/JCO.2017.77.3184" rel="noopener noreferrer">Pembrolizumab for Patients With Refractory or Relapsed Thymic Epithelial Tumor: An Open-Label Phase II Trial</a>" on JCO.org

Risky Business: PD-1 Immune Checkpoint Blockade in Thymic Epithelial Neoplasms

The Journal of Clinical Oncology podcast, hosted by Dr. Shannon Westin and Dr. Davide Soldato, presents analyses and discussions centered on the latest findings published in ASCO's esteemed Journal of Clinical Oncology. Through scholarly discourse and examination, this podcast is your resource for navigating oncological advancements and how they impact clinical practice.

The JCO Podcast also features in depth summaries and interviews hosted by the year's fellows in the series, JCO Article Insights.

Medicine

Health & Fitness

The Journal of Clinical Oncology podcast, hosted by Dr. Shannon Westin and Dr. Davide Soldato, presents analyses and discussions centered on the latest findings published in ASCO's esteemed Journal of Clinical Oncology. Through scholarly discourse and examination, this podcast is your resource for navigating oncological advancements and how they impact clinical practice. The JCO Podcast also features in depth summaries and interviews hosted by the year's fellows in the series, JCO Article Insights.

Share Risky Business: PD-1 Immune Checkpoint Blockade in Thymic Epithelial Neoplasms

Sign up to save your podcasts

Risky Business: PD-1 Immune Checkpoint Blockade in Thymic Epithelial Neoplasms

Risky Business: PD-1 Immune Checkpoint Blockade in Thymic Epithelial Neoplasms

More shows like Journal of Clinical Oncology (JCO) Podcast

NPR News Now

JAMA Editors' Summary

NEJM This Week

JAMA Clinical Reviews

ASCO Daily News

The Daily

ASCO Guidelines

ASCO Education

Annals On Call Podcast

JAMA Medical News

Harrison's PodClass: Internal Medicine Cases and Board Prep

Run the List

Two Onc Docs

Oncology Brothers: Practice-Changing Cancer Discussions

The Headlines